Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04847531 · ClinicalTrials.gov registry record
REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 1,006,361
- Enrollment target
NCT04847531: Completed study, sponsored by AstraZeneca.
NCT04847531 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 1,006,361 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04847531 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 1,006,361 participants
- Enrollment target
Study Summary
This is a retrospective, multinational, non-interventional, observational study. A series of cohort studies will be conducted to assess the prevalence of undiagnosed stage 3 CKD in each region. The study will also assess the current state of CKD management in patients with undiagnosed CKD
Primary Outcome
Undiagnosed stage 3A-3B CKD identified as having no healthcare encounter with a diagnosis code for CKD any time before or up to six months post index date (date of second consecutive estimated glomerular filtration rate \[eGFR\] value indicating stage 3 CKD recorded at least 90 days after the first abnormal eGFR value), assessed overall and by calendar year
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,006,361 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2023-11-13 |
What the finished NCT04847531 record still lists
NCT04847531 is an observational study that tracks outcomes without assigning an intervention. Its 1,006,361 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04847531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04847531 about?
NCT04847531 is a clinical study titled "REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease". This is a retrospective, multinational, non-interventional, observational study. A series of cohort studies will be conducted to assess the prevalence of undiagnosed stage 3 CKD in each region. The study will also assess the current state of CKD management in patients with undiagnosed CKD
What is the current status of trial NCT04847531?
This trial is currently completed. The enrollment target is 1,006,361 participants. The study started on 2020-12-15. Estimated completion is 2023-11-13.
Who is sponsoring clinical trial NCT04847531?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05066763 · 1,000,000 participants
Parkinson's Foundation Surveys
- NCT07075341 · 1,000,000 participants
Healthy Living BEYOND Weight Study
- NCT07224685 · 1,000,000 participants
A Study of Mayo Clinic CV Research Heart & Voice Study
- NCT06029933 · 960,000 participants
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI